The RTFCCR/Blood Cancer United Patient-Focused Prevention Program will not open for new applications this year.
In a joint collaboration, Blood Cancer United and RTFCCR aim to stimulate innovative and clinically relevant cancer research that has the highest potential for near-term patient impact in terms of clinical application, therapeutic outcomes and quality of life.
These grants aspire to advance clinical cancer research worldwide that aims to prevent blood cancers from either occurring initially in healthy individuals (no neoplasm detected), advancing to full-blown blood cancers in patients with benign conditions, or blocking reoccurrence of blood cancer after therapy.
Find out more about the Prevention Awards or browse our resources for current Prevention awardees below.
The Rising Tide Foundation for Clinical Cancer Research and Blood Cancer United partner in an international competitive grant to advance breakthroughs in prevention for blood cancers. The grant is focused on addressing four critical topics and is endowed with a total of USD $3 million.
The grants must be translational in nature. Ideally, the applications will have a clinical trial proposed, or could lead to a clinical trial. Applications that are solely laboratory-based without consideration of using patient samples or future clinical testing will not be accepted for review.
RFP suggested topics
- Clinical trials: Examine the use of pharmaceuticals, nutraceuticals, or life-style changes as prevention of blood cancer onset, progression to full blown disease, or relapse. Applications could be for any premalignant conditions before the onset of blood cancer or after successful blood cancer therapy (i.e. prevention of relapse). Therapeutics could include small molecules, biologics, or immunotherapeutics.
- Biomarker evaluation: Develop and apply sensitive minimally invasive methods to detect precursor conditions before disease onset or sustained after successful therapy
- Use experimental systems to identify safe and effective therapeutic strategies to eliminate mutant clones early in disease stages or prevent recurrence of disease that could justify a clinical trial in prevention
- Drug the undruggable: Develop novel strategies to remove/deactivate tumor drivers that initiate, or predispose to, disease onset and/or develop novel approaches, such as synthetic lethality, to achieve the same goal.
Get information about other programs, and about applying for Blood Cancer United research funding,
Grant requirements
Reporting schedule: Rising Tide Foundation (RTF) grant reporting is conducted through https://proposalcentral.com. Please log in to this site to review RTF's reporting requirements and schedule for your grant. The Blood Cancer United reporting schedule for your particular grant is also printed on your Grant Agreement and available under Reports Due in the Blood Cancer United Research Portal (FLUXX).
Report submission: You can access the Blood Cancer United Research Portal (FLUXX) using the same username and password that were used during the application process. Individuals responsible for submitting reports must be manually added to each individual grant record in our system in order for them to have reporting access for each grant. Contact [email protected] to update reporting access for your grant.
Progress Reports and Publications Reports should be submitted by the researcher (the PI). Financial Reports should be submitted by the financial officer.
Researchers and administrators should be careful to follow all instructions on the report web form and downloadable template. Reports that fail to follow instructions will be returned for revision, which may delay grant payment. Do not save templates for future use; the templates are subject to change and therefore must be newly downloaded for each submission.
Grant payment
Blood Cancer United pays research grants quarterly in March, June, September, and December. Payments are contingent upon reporting requirements; all report approvals must be up to date in order for payment to be processed. A list of sent payments can be viewed in the Blood Cancer United Research Portal (FLUXX) under Dispersed Payments.
Transfers
Blood Cancer United and RTF approval is required at least 30 days prior to an award's transfer to a new institution or laboratory. Only one transfer per grant is allowed. In order to submit a request for transfer, complete a Special Requests report in the Blood Cancer United Research Portal (FLUXX). Your request will be reviewed, and you will receive a notification from Blood Cancer United with the results of the review or with a request for more information. Approval is contingent upon continued research support and sponsorship, fitness of the new research environment, and circumstances of your award type and timing of the request (see your Grant Agreement for more details).
Transfer to another investigator may be allowed if the original grantee is unable to continue the project (e.g. if they move to a new institution unequipped for the project). Contact [email protected] to inquire about a grantee transfer.
Leaves of absence
Blood Cancer United approval is required at least 30 days prior to the interruption of an award. Leaves of absence may not exceed 1 year in duration. In order to submit a request for leave of absence, complete a Special Requests report in the Blood Cancer United Research Portal (FLUXX). If the request is approved, funding of the award will be suspended during the leave period, and the grant term will be extended for a period equal to the duration of the suspension (e.g. following an approved 1-year leave of absence, an award originally scheduled to end 6/30/2022 will end 6/30/2023).
If you have questions regarding your grant that are not addressed here, please contact the Research Administration Team at [email protected].